GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (LTS:0HB0) » Definitions » Policy Acquisition Expense

Agios Pharmaceuticals (LTS:0HB0) Policy Acquisition Expense


View and export this data going back to 2018. Start your Free Trial

What is Agios Pharmaceuticals Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Agios Pharmaceuticals (LTS:0HB0) Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.